Rey J F, Greff M, Picazo J
Dig Dis Sci. 1986 Apr;31(4):355-60. doi: 10.1007/BF01311669.
The amino acid sequence (1-21) of glucagon has been shown to have full spasmolytic action in animal studies but no metabolic effect. The motor activity of the sphincter of Oddi was measured during ERCP with manometric recordings of sphincter pressure. Then glucagon-(1-21)-peptide was given as a bolus intravenous injection; serial blood samples were taken to determine glucagon-like immunoreactivity. The spasmolytic effect of glucagon-(1-21)-peptide began 15 sec after injection and lasted up to 22 min at the higher doses. The basal pressure of the sphincter of Oddi was decreased by 31-56% after administration of glucagon-(1-21)-peptide. Phasic sphincter of Oddi pressure and wave frequency were also affected. In conclusion, glucagon-(1-21)-peptide has a relaxing effect on the human sphincter of Oddi and might emerge as an alternative to glucagon or other spasmolytic drugs for obtaining selective relaxation of the biliary tract.
在动物研究中已表明,胰高血糖素的氨基酸序列(1 - 21)具有完全的解痉作用,但无代谢效应。在内镜逆行胰胆管造影(ERCP)期间,通过测量括约肌压力的测压记录来测定Oddi括约肌的运动活性。然后静脉推注胰高血糖素 -(1 - 21)肽;采集系列血样以测定胰高血糖素样免疫反应性。胰高血糖素 -(1 - 21)肽的解痉作用在注射后15秒开始,在较高剂量下可持续长达22分钟。给予胰高血糖素 -(1 - 21)肽后,Oddi括约肌的基础压力降低了31% - 56%。Oddi括约肌的相性压力和波频率也受到影响。总之,胰高血糖素 -(1 - 21)肽对人Oddi括约肌有松弛作用,可能会成为胰高血糖素或其他解痉药物的替代品,用于实现胆道的选择性松弛。